Helping you make wiser investment decisions

BioNTech, through Fosun deal, pledges 100M coronavirus vaccine doses for China

December 16, 2020 Fraiser Kansteiner


Pfizer and its German mRNA partner BioNTech have started racking up authorizations for their COVID-19 vaccine, with shots already going into patients’ arms in countries like the U.K. and the U.S. Now, BioNTech has struck a deal to supply initial doses in China, where the vaccine is currently in mid-stage testing. 

BioNTech, through its arrangement with local drugmaker Shanghai Fosun, will supply Mainland China with an initial 100 million doses of its mRNA vaccine, BNT162, in 2021—should the shot pass muster with domestic regulators.

BioNTech will source the doses from its production facilities in Germany, the company said in a release.

Sponsored By Parexel

Is your FSP vision 2020?

At Parexel, we get the right people to you, so you can get the right treatment to your patients. Our functional service provider (FSP) outsourcing has evolved with biopharma’s changing needs, so sponsors can efficiently manage operations through access to experts, resource flexibility, and reduced labor costs. Our latest whitepaper discusses the current FSP models and provides expert tips for choosing the right one.

The two companies struck a strategic collaboration back in March to develop and market a potential COVID-19 vaccine based on BioNTech’s mRNA platform. Under the deal, Fosun is on the hook for up to $135 million in upfront and future milestone payments for an authorized shot, which it would commercialize in China.

RELATED: China’s Sinovac sees speedy immune response with COVID-19 shot in early trials

In July, the Chinese firm registered a phase 1 trial of BioNTech’s first vaccine candidate, BNT162b1, with local authorities. Less than a week later, BioNTech and its partner Pfizer announced they had selected BNT162b2 as the candidate to advance to phase 2/3, linking it to lower rates of side effects. 

Fosun itself made the switch in early November, opting against further development of BNT162b1 as it moved ahead with the partners’ second candidate. 

RELATED: BioNTech buys Novartis plant for COVID-19 vaccine, eyes capacity of up to 750M doses

Later that same month, BioNTech and Fosun kicked off a phase 2 trial of BNT162b2 in Jiangsu Province, China. The study, meant to assess the safety and immunogenicity of the shot, has commenced with the recruitment of 960 healthy participants between the ages of 18 to 85 years old, BioNTech said.

Elsewhere, authorizations for Pfizer and BioNTech’s shot have started trickling in. The U.K. on Dec. 2 became the first Western nation to clear the shot for emergency use. That nod was followed by a Dec. 11 U.S. authorization for the vaccine—a little more than 24 hours after it won the support of the FDA’s advisory panel. 



Source link